2. Academic Validation
  3. New Agents in Development for Sepsis: Any Reason for Hope?

New Agents in Development for Sepsis: Any Reason for Hope?

  • Drugs. 2020 Nov;80(17):1751-1761. doi: 10.1007/s40265-020-01402-z.
Philippe Vignon 1 2 3 4,  Pierre-François Laterre 5,  Thomas Daix 6 7 8,  Bruno François 6 7 8
Affiliations

Affiliations

  • 1 Medical-Surgical Intensive Care Unit, Dupuytren Teaching Hospital, 87000, Limoges, France. philippe.vignon@unilim.fr.
  • 2 Inserm CIC 1435, Dupuytren Teaching Hospital, 87000, Limoges, France. philippe.vignon@unilim.fr.
  • 3 Inserm UMR 1092, Dupuytren Teaching Hospital, 87000, Limoges, France. philippe.vignon@unilim.fr.
  • 4 Réanimation Polyvalente, CHU Dupuytren, 2 Avenue Martin Luther king, 87042, Limoges, France. philippe.vignon@unilim.fr.
  • 5 St Luc University Hospital, Université Catholique de Louvain, Avenue Hippocrate 12, 1200, Brussels, Belgium.
  • 6 Medical-Surgical Intensive Care Unit, Dupuytren Teaching Hospital, 87000, Limoges, France.
  • 7 Inserm CIC 1435, Dupuytren Teaching Hospital, 87000, Limoges, France.
  • 8 Inserm UMR 1092, Dupuytren Teaching Hospital, 87000, Limoges, France.
PMID: 32951149 DOI: 10.1007/s40265-020-01402-z
Abstract

Sepsis is a syndrome which is defined as a dysregulated host response to Infection leading to organ failure. Since it remains one of the leading causes of mortality worldwide, numerous drug candidates have already been tested, and continue to be developed, as potential adjunct therapies. Despite convincing mechanisms of action and robust pre-clinical data, almost all drug candidates in the field of sepsis have failed to demonstrate clinical efficacy in the past two decades. Accordingly, the development of new sepsis drugs has markedly decreased in the past few years. Nevertheless, thanks to a better understanding of sepsis pathophysiology and pathways, new promising drug candidates are currently being developed. Instead of a unique sepsis profile as initially suspected, various phenotypes have been characterised. This has resulted in the identification of multiple targets for new drugs together with relevant biomarkers, and a better understanding of the most appropriate time to intervention. Within the entire sepsis drugs portfolio, those targeting the immune response are probably the most promising. Monoclonal Antibodies targeting either cytokines or infectious agents are undoubtedly part of the potential successful therapeutic classes to come.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z